Stage Lung Cancer Research Articles

Proposal for a standardized methodology for performing endobronchial ultrasound-guided mediastinal cryobiopsy: a four-step approach.

Endobronchial ultrasound (EBUS)-guided mediastinal cryobiopsy is a novel technique that increases the accuracy of diagnosing most pathologies that affect the mediastinum. Although EBUS-guided transbronchial needle aspiration (EBUS-TBNA) is the first choice in the diagnosis of mediastinal pathology, mediastinal cryobiopsy offers a larger and higher quality biopsy with minimal artifacts and no crushing when compared to conventional cytological samples obtained through EBUS-TBNA. It is particularly valuable in pathologies where EBUS-TBNA has diagnostic limitations, such as lymphoproliferative diseases, benign granulomatous conditions like sarcoidosis and silicosis, some rare infectious processes, metastases from rare non-pulmonary tumors, and in advanced stages of non-small cell lung cancer (NSCLC) where immunohistochemistry and molecular analysis are essential for personalized treatment. Therefore, mediastinal cryobiopsy seems to play a crucial role in these challenging scenarios. However, there is ongoing debate in the field of interventional pulmonology regarding the best approach for obtaining a mediastinal cryobiopsy. Some interventional pulmonologists use a high-frequency needle knife to create an incision in the tracheobronchial wall adjacent to the mediastinal lesion before inserting the cryoprobe, while others use a needle to create a pathway to the target area. There are also variations in the use of endoscopic or ultrasound imaging for guidance. In this article, we aim to review the current literature on different methods of performing mediastinal cryobiopsy and share our own clinical experience and methodology in a systematic way for its implementation in a safe, fast, and effective way.

Outcomes of Patients Undergoing Segmentectomy for Occult Node-Positive Clinical Stage IA Lung Cancer

BackgroundResults of recent clinical trials suggest that segmentectomy may be an acceptable alternative to lobectomy for selected patients with early-stage non-small cell lung cancer (NSCLC). Increased use of segmentectomy may result in a concomitant increase in occult node-positive (N+) disease on surgical pathology examination. The optimal management for such patients remains unknown. MethodsClinicopathologic data were abstracted from a prospective institutional database to identify patients with pathologic N+ disease after segmentectomy for cT1 N0 M0 NSCLC. Propensity score matching identified a comparable lobectomy cohort for assessment of cumulative incidence of recurrence and overall survival (OS). ResultsOf 759 included patients, 27 (4%) had nodal upstaging on the final pathology report. Of these 27 patients, 4 (15%) had skip metastasis to N2 stations, and 20 (74%) received adjuvant therapy; no completion lobectomies were performed. Ten patients (37%) had disease recurrence: 3 isolated locoregional (11%) and 7 distant (26%). The median time to recurrence among patients with recurrence was 1.8 years; OS after recurrence was 3.4 years. After 5:1 matching with 109 patients who underwent lobectomy, all variables were balanced between the groups, except pathologic N2 stage and open surgical approach. The 5-year cumulative incidence of recurrence was not significantly different between segmentectomy and lobectomy (42% vs 52%, respectively; Gray’s P = .1). The 5-year OS (63% and 50%) and rate of locoregional recurrence (12% vs 13%) were not statistically different between the groups. ConclusionsPatients with occult N+ disease after segmentectomy for cT1 N0 M0 NSCLC had limited isolated locoregional recurrences and outcomes similar to those in patients who underwent lobectomy. Lobectomy may not provide an advantage in these patients.

Surgical access to the mediastinum-all roads lead to Rome: a literature review.

The mediastinum is a complex, heterogeneous area, which leads vertically across the thoracic cavity between the bilateral mediastinal pleurae, connecting the head and neck region with the thoracic cavity. Different classifications have been published to differentiate between the so-called mediastinal compartments while the most used classification surely is the 4-compartments Gray`s classification, dividing it into the superior, anterior, middle and posterior mediastinum. Mediastinal abnormalities include infections (mediastinitis) and solid or cystic mediastinal masses. These masses can be divided into benign and malignant lesions originating from mediastinal structures/organs or represent manifestations of metastatic disease, often metastatic non-small cell lung cancer (NSCLC). This review aims to explore the different mediastinal pathologies along with indications and surgical approaches. We performed literature research in PubMed, MEDLINE, Embase, CENTRAL, and CINAHL databases. Only papers written in English were included. Depending on the indication for surgical intervention and the localization of the pathology, surgical approach may differ immensely. Mediastinal staging of lung cancer, primary lesions of the mediastinum, mediastinitis and traumatic mediastinal injuries display the most frequent indications for mediastinal surgery. Surgical approaches trend towards minimally invasive, video- or robotic-assisted techniques and are becoming increasingly refined to adapt to the special characteristics of the mediastinum. However, certain indications still require open access for best possible mediastinal exposure or oncological reasons. To guide optimal surgical approach selection to the mediastinum, the following overview will present all published surgical approaches to the mediastinum and discuss their practical relevance and indications aiming to help surgeons in the management of patients with mediastinal pathologies who should undergo surgery.

Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer.

8009 Background: Lung cancer incidence in Taiwan has been rising with the epidemiological profiles distinct from Western country. Notably, nonsmoking lung cancers accounts for more than 60% and half of lung cancers were diagnosed in advanced stages. For early detection, a national program is therefore initiated to offer biennial low-dose computed tomography (LDCT) screening for heavy smokers and subjects with lung cancer family history (LCFH). Here, we report basic screening findings, analyze relevant effectiveness in reducing advanced lung cancer, and project the potential benefit of mortality reduction. Methods: Taiwan National Lung Cancer Early Detection Program was launched on July 1, 2022 to offer heavy smokers (30 pack-years) and nonsmokers (including light smokers) with a LCFH aged 45-74 years for female and aged 50-74 years for male. This is a continuous screening program using before and after study design for evaluation. We provided the overall first-year basic screening findings until Dec 31, 2023 and did per protocol analysis of stage II+ cancer reduction in comparison with tumor stage distribution in the year preceding the introduction of the national program. The corresponding findings were presented for subjects with LCFH and heavy smokers. The result for heavy smoker was compared with those per-protocol findings from previous randomized controlled trials. The potential mortality reduction was further projected. Results: A total of 78,000 individuals participated in this program, male 44,381 (56.9%) female 33,619 (43.1%); 31,111 participants (39.9%) were heavy smokers, 43,853 (56.2%) nonsmokers but with a LCFH, and 3,036 (3.9%) had both risk factors. Lung cancer confirmed in 956 subjects by surgery or biopsy, 85.0% were stage 0-1. The lung cancer detection rate was 1.2%. Subjects with a LCFH exhibited a higher detection rate (overall: 1.6%, nonsmokers: 1.7% and light smokers 0.9%) compared to heavy smokers (0.7%) and both (1.1%). Early detection of LDCT led to a statistically significant 77% (51%-89%) of reducing advanced stage of lung cancer, 53% (-3%-78%) reduction for heavy smokers, consistent with the corresponding 36%-64% reduction derived from the NLST trial and the Nelson trial, and 85% (67%-93%) reduction for nonsmokers with a LCFH. The benefit of reducing stage II or severe in conjunction with five-year stage-specific survival rate further projected 55% (10%-78%) of mortality reduction from lung cancer. Conclusions: This is the first large-scale LC screening service enrolling 40% heavy smokers and 60% non-smoker with a LCFH. The potential effectiveness of early detection was demonstrated for both targets. As the results based on per-protocol analysis for heavy smoker were consistent with those of previous evidence-based studies the similar and significant intention-to-treat results as before while waiting for the subsequent follow-up would be expected.

Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial.

Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial.

Efficacy of compound pholcodine syrup and compound codeine phosphate oral solution on lung cancer cough.

e20548 Background: To assess the therapeutic effect of compound pholcodine syrup and compound codeine phosphate oral solution on lung cancer cough. Methods: A total of 60 patients with diagnosed middle-advanced stage lung cancer accompanied with lung cancer cough from Jan, 2022 to May, 2022 were enrolled . According to the method of random number table, the patients were divided into two groups: observation group and control group. Observation group received compound pholcodine syrup treatment, while control group received compound codeine phosphate oral solution treatment. The dosage of the two drugs was 15 ml each time, 3 times a day, and the treatment course was 5 days. The antitussive effectiveness, cough severity and quality of life , were observed and compared between the two groups before and after the 3 days and 5 days treatment, respectively. Results: All 60 patients completed the treatment. Both two groups were effective in controlling lung cancer cough. After the 3 days treatment, the antitussive effective rates of the observation group and the control group were 83.3% (25/30) and 73.3% (22/30), respectively, with no statistical significance ( P= 0.347). After the 5 days treatment, the antitussive effective rates of observation group and control group were 90.0% (27/30) and 86.6% (26/30), respectively, with no statistical significance ( P= 0.687). There was no significant difference in the composition of patient cough severity between observation group[moderate and severe cough, 56.7% (17/30) ] and control group [moderate and severe cough, 67.7% (20/30) ]. After 3 days treatment, cough symptoms were relieved in both groups. Patients with mild cough accounted for 73.3% (22/30) in the observation group and 56.7% (17/30) in the control group, the difference was not statistically significant ( P= 0.331). What's more, after 5 dyas treatment, there was also no significant difference( P= 0.067)between observation group[mild cough, 86.7%(26/30)] and control group [mild cough, 66.7%(20/30)] . In the meantime, there were no significant differences in the physiological score, psychological score, social score and total score of the Leicester Cough Questionnaire in Mandarin-Chinese scale before the treatment, after 3 days and 5 days treatment between the two groups (all P > 0.05). Patients in the observation group had a lower incidence of xerostomia (0.0% vs 20.0 %, P= 0.024) and constipation (0.0% vs 20.0 %, P= 0.024) than control group. Conclusions: Compound pholcodine syrup and compound codeine phosphate oral solution are effective in treating lung cancer cough with similar antitussive effectiveness. Compound pholcodine syrup has a lower incidence of xerostomia and constipation than control group, which indicates that the security may be better. Clinical trial information: ChiCTR2300076684.

Influence of sociodemographic factors on time to diagnosis and treatment among members of a large national payor diagnosed with lung cancer.

e23048 Background: Diagnostic and treatment delays may be associated with later stage lung cancer diagnosis. This study explores the time from lung cancer screening to biopsy and biopsy to treatment in members of a national health plan diagnosed with lung cancer. Methods: De-identified administrative records of Medicare, Medicaid and Commercial fully-insured (C-FI) members with a claim for lung cancer between January 2020 and December 2022 were retrospectively analyzed. Poisson regression modeling determined duration (days) from screening to biopsy and biopsy to treatment initiation by insurance type group controlling for covariates. Between-group differences in duration was estimated by exponentiating the model estimate and converting to a percentage change, which was then applied to the mean days to event. Time-to-event modelling was conducted with Cox Proportional and Aelen’s Additive Hazard models. P< 0.05 was considered significant. Results: 8,221 members (C-FI: 402; Medicare: 7,103; Medicaid: 716) with a diagnosis of lung cancer were evaluated. Mean duration between screening and biopsy was 34.3 days (95% confidence interval [CI]: 32.8-35.8). Compared to C-FI members, Medicaid and Medicare members experienced shorter duration between screening to biopsy by -14.0 days (95% CI: 13.1-14.9) and -18.9 days (95% CI: 18.2-19.5), respectively (both P< 0.0001). Gender, language, age, and race were associated with time to biopsy (all P< 0.001). Mean duration between biopsy and treatment was 37.9 days (95% CI: 36.8-39.0). Compared to C-FI members, Medicare and Medicaid members experienced a longer duration between biopsy to treatment by +14.6 days (95% CI: 12.1-17.3) and +22.5 days (95% CI: 19.4-25.8), respectively (both P< 0.0001). Compared to C-FI members, Medicaid members had a higher risk of not receiving treatment (Hazard ratio [HR] = 0.831; 95% CI: 0.735-0.939; P= 0.003). Among the total sample, males were more likely to receive treatment at any time compared to females (HR = 1.067; 95% CI: 1.021-1.114; P= 0.0035). Conclusions: This real-world evaluation suggests that insurance type is associated with the timeline of screening to biopsy and biopsy to treatment initiation. Medicaid and Medicare members had a shorter time from screening to biopsy compared to C-FI; however, a longer duration from biopsy to treatment initiation was experienced. Future studies will explore if these differences translate to variations in health outcomes and identify potential interventions that aim to improve time from biopsy to treatment initiation.

Improving LDCT screening rates within a large multidisciplinary community based practice using integrated ACR accredited imaging centers.

e13582 Background: Lung cancer remains the leading cause of cancer-related death in the US, accounting for about 22% of such deaths. Lung cancer detected by low-dose computed tomography (LDCT) screening is discovered at an early stage 64-85% of the time. The benefits of LDCT screening have been demonstrated in numerous trials, but there has been difficulty in establishing programs that screen a high percentage of eligible patients. We present data from the first 18 months of our lung cancer screening program that is designed to provide the highest quality screening, follow-up and access to prevention, diagnosis, and treatment including clinical trials within their local communities. Methods: New York Cancer and Blood Specialists (NYCBS) is a community practice with over 50 locations across NY. While most lung cancer screening programs are hospital-based, NYCBS has a series of American College of Radiology (ACR) accredited imaging centers that perform these screenings and are closely affiliated with oncology, primary care, Ob-Gyn, nephrology, urology and other specialty medical and surgical practices. These centers are strategically located in areas that have high rates of tobacco use as suggested by heat map data from the NY City Community Health Survey . Upon initial patient presentation, all NYCBS and affiliated sites screen patients with tablet-based questionnaires that prompt additional questions during follow-up appointments. Patients with positive findings are discussed during a monthly, system-wide multidisciplinary lung nodule review conference. Follow-up interventions include referrals to pulmonology, interventional radiology, or further imaging with PET/CT. Per ACR guidelines, patients not requiring acute intervention continue with follow-up CT. Results: In 2023, 29,501 patients were screened with an in-office questionnaire. Of those patients, 3,606 were eligible for screening, 225 declined, and 896 (29%) high risk patients proceeded to undergo LDCT screening. In screened patients, 128 underwent follow-up CT, 36 patients had findings requiring immediate intervention, and 6 were diagnosed with lung cancer. 5 of these patients were diagnosed with stage I and 1 patient was diagnosed with stage IV lung cancer. Conclusions: LDCT screening is a proven method to discover early stage lung cancer and improve the survival rate of diagnosed patients but has not been well adopted in practice. With access to a diverse array of multidisciplinary practices across NY and integrated accredited imaging centers, we have increased the accessibility of lung cancer screening and improved transitions to follow-up care. Nationally, only 4.5% of patients at high risk are screened, however, we found that with our approach to patient care, we have achieved among the highest reported screening rates in eligible individuals.

Establishment and validation of a clinicopathological prediction model for postoperative recurrence of stage IA lung adenocarcinoma.

With the popularization of low-dose spiral computed tomography (CT), an increasing number of stage IA lung cancers have been discovered. Patients with stage IA lung adenocarcinoma who undergo radical surgical resection tend to have a favourable prognosis. However, A significant proportion of patients undergo postoperative recurrence and metastasis. The purpose of this study was to screen out the risk factors in patients with stage IA lung adenocarcinoma and establish a nomogram model to help clinicians identify high-risk patient groups. A nomogram was conducted based on a retrospective study of 731 patients with stage IA lung adenocarcinoma. Concordance index (C-index), clinical decision analysis, receiver operating characteristic (ROC) curve and calibration curve were used to evaluate the discrimination and calibration of the nomogram. Survival curves were drawn by Kaplan-Meier method, and significance was determined by log-rank test. According to nomogram scores, the patients were divided into low- and high-risk subgroups. The internal and external cohorts included 731 and 235 eligible patients. In univariate and multivariate analyses, the independent factors for recurrence-free survival (RFS) were all selected in the nomogram. C-indexes of the nomogram were 0.812 (95% confidence interval: 0.756-0.868) and 0.817 in the internal and external validation, respectively, showing that the prominent prediction performance was great. Nomogram scores showed that patients in the low-risk group (5-RFS rate, 0.797 to 0.99) had better RFS than patients in the high-risk group (5-RFS rate, 0.10 to 0.797) (P<0.001). A nomogram model was established that can be beneficial to evaluate RFS in patients with stage IA lung adenocarcinoma after curative resection. It can be of value in helping clinicians develop treatment strategies to improve patient survival.

Presentation and management of delayed bronchopleural fistula after pulmonary lobectomy: a case report

BackgroundLung cancer is the second most diagnosed cancer and the leading cause of cancer deaths worldwide. Surgical lung resection is the best treatment modality in the early stages of lung cancer as well as in some locally advanced cases. Postoperative air leak is one of the most common complications after pulmonary resection with incidence ranging between 20 and 33%. The majority of air leaks seal, within 5 days after surgery, on their own by conservative management. However, at least 5% of patients still have prolonged air coming out from the residual lung at discharge. This report describes the management of a thin lady with right lung cancer who underwent a right lower lobectomy and then suffered from a delayed air leak 7 weeks after surgery and required extensive thoracic and general surgery collaboration.Case presentationA 72-year-old heavy smoker female patient diagnosed with stage I lung cancer underwent right robotic-assisted thoracoscopic surgery converted to thoracotomy because of a fused fissure, right lower lobectomy, and mediastinal lymphadenectomy presented with delayed air leak 49 days after surgery. VATS decortication and mechanical pleurodesis were done 2 weeks after unsuccessful conservative treatment. Still, the lung failed to expand four weeks later so the patient was sent to surgery; she is underweight (BMI of 18) with not many options for a big flap to fill the chest cavity empty space. Accordingly; the decision was to use multiple pedicle flaps; omentum, intercostal muscle, and serratus anterior muscle to cover the bronchopleural fistulas and fill the pleural space in addition to mechanical and chemical pleurodesis. Full expansion of the lung was obtained. The patient was discharged on Post-Operative day 5 without remnant pneumothorax.ConclusionsAir leaks After lobectomy usually presents directly postoperatively; various management options are available ranging from conservative and minimally invasive to major operative treatment. We presented what we believe was unusual delayed bronchopleural fistula post-lobectomy in a thin lady which demonstrates clearly how a delayed air leak was detected and how collaborative efforts were crucial for delivering high-quality, safe, and patient-centered care till treated and complete recovery.

Optimizing double-layered convolutional neural networks for efficient lung cancer classification through hyperparameter optimization and advanced image pre-processing techniques.

Lung cancer remains a leading cause of cancer-related mortality globally, with prognosis significantly dependent on early-stage detection. Traditional diagnostic methods, though effective, often face challenges regarding accuracy, early detection, and scalability, being invasive, time-consuming, and prone to ambiguous interpretations. This study proposes an advanced machine learning model designed to enhance lung cancer stage classification using CT scan images, aiming to overcome these limitations by offering a faster, non-invasive, and reliable diagnostic tool. Utilizing the IQ-OTHNCCD lung cancer dataset, comprising CT scans from various stages of lung cancer and healthy individuals, we performed extensive preprocessing including resizing, normalization, and Gaussian blurring. A Convolutional Neural Network (CNN) was then trained on this preprocessed data, and class imbalance was addressed using Synthetic Minority Over-sampling Technique (SMOTE). The model's performance was evaluated through metrics such as accuracy, precision, recall, F1-score, and ROC curve analysis. The results demonstrated a classification accuracy of 99.64%, with precision, recall, and F1-score values exceeding 98% across all categories. SMOTE significantly enhanced the model's ability to classify underrepresented classes, contributing to the robustness of the diagnostic tool. These findings underscore the potential of machine learning in transforming lung cancer diagnostics, providing high accuracy in stage classification, which could facilitate early detection and tailored treatment strategies, ultimately improving patient outcomes.

Screening for lung cancer using thin-slice low-dose computed tomography in southwestern China: a population-based real-world study.

Lung cancer is one of the most common malignant tumors threatening human life and health. At present, low-dose computed tomography (LDCT) screening for the high-risk population to achieve early diagnosis and treatment of lung cancer has become the first choice recommended by many authoritative international medical organizations. To further optimize the lung cancer screening method, we conducted a real-world study of LDCT lung cancer screening in a large sample of a healthy physical examination population, comparing differences in lung nodules and lung cancer detection between thin and thick-slice LDCT scanning. A total of 29 296 subjects who underwent low-dose thick-slice CT scanning (5 mm thickness) from January 2015 to December 2015 and 28 058 subjects who underwent low-dose thin-slice CT scanning (1 mm thickness) from January 2018 to December 2018 in West China Hospital were included. The positive detection rate, detection rate of lung cancer, pathological stage of lung cancer, and mortality rate of lung cancer were analyzed and compared between the two groups. The positive rate of LDCT screening in the thin-slice scanning group was significantly higher than that in the thick-slice scanning group (20.1% vs. 14.4%, p < 0.001). In addition, the lung cancer detection rate in the thin-slice LDCT screening positive group was significantly higher than that in the thick-slice scanning group (78.0% vs. 52.9%, p < 0.001). The screening positive rate of low-dose thin-slice CT scanning is higher and more early-stage lung cancer (IA1 stage) can be detected in the screen-positive group.

The role of seven tumor-associated autoantibodies in the diagnosis, staging and treatment guidance of lung cancer

BackgroundThis study assessed the diagnosis, staging and treatment guidance of lung cancer (LC) based on seven tumor-associated autoantibodies (TAAbs) —p53, PGP9.5, SOX2, GBU4-5, MAGE A1, CAGE, and GAGE7.MethodsELISA was used to determine the TAAb serum levels in 433 patients diagnosed with LC (161 surgical patients) and 76 patients with benign lung disease (16 surgical patients). The statistical characteristic of the TAAbs was compared among patients with different clinicopathological features. Pre- to postoperative changes in TAAb levels were analyzed to determine their value of LC.ResultsAmong all patients, the positive rate of the seven TAAbs was 23.4%, sensitivity was 26.3%, accuracy was 36.3%, specificity was 93.4%, positive predictive value was 95.8%, and negative predictive value was 18.2%; the positive rate for the LC group (26.3%) was significantly higher than that for the benign group (6.6%; P < 0.001). Significant differences in the positive rate of the seven autoantibodies according to age (P < 0.001), smoking history (P = 0.009) and clinical LC stage (P < 0.001) were found. Smoking was positively associated with the positive of TAAbs (Τ = 0.118, P = 0.008). The positive rates of the seven TAAbs for squamous carcinoma (54.5%), other pathological types (44.4%) and poorly differentiated LC (57.1%) were significantly higher than those for the other types. The positive rate of GBU4-5 was highest among all TAAbs, and the SOX2 level in stage III-IV patients was much higher than that in other stages. For patients undergoing surgery, compared with the preoperative levels, the postoperative levels of the 7 markers, particularly p53 (P = 0.027), PGP9.5 (P = 0.007), GAGE7 (P = 0.014), and GBU4-5 (P = 0.002), were significantly different in the malignant group, especially in stage I-II patients, while no clear pre- to postoperative difference was observed in the benign group.ConclusionsWhen the seven TAAbs was positive, it was very helpful for the diagnosis of LC. The 7 TAAbs was valuable for staging and guiding treatment of LC in surgical patients.

Prognostic value of biohybrid screening results for assessing cancer risk using the example of lung cancer

Introduction. One of the leading places in the structure of socially significant diseases in the Russian Federation is occupied by malignant neoplasms, among which cancer of the trachea, bronchi and lung occupies the first place in terms of prevalence. Screening for lung cancer is not carried out at the federal level in Russia; recommended screening measures include questionnaires to identify risk factors for the development of the disease (including occupational) and the formation of dispensary observation groups. The study aims to assess the prognostic value of a new method of biohybrid screening of lung cancer by exhaled air. Materials and methods. Scientists conducted a study at the National Medical Research Center of Oncology of the Ministry of Health, Russian Federation, with the participation of 24 conditionally healthy volunteers and 5 patients diagnosed with lung cancer in the early stages of the disease. The design of the study is simultaneous (on-line) with blinding; experts estimated the risk of systematic errors at 10 points on the QUADAS scale. The authors examined exhaled air samples on a gas analyzer (biohybrid detector) of the BGS-APK 02SZZ model, in which the sensor were animals — gray domesticated rats (Rattus norvegicus) with microelectrode matrices implanted into the olfactory bulb, and which were in the internal (ventilated) space of the analyzer in a state of drug anesthesia. The conclusion about the presence or absence of a risk of lung cancer was formed by an artificial neural network of the analyzer, at the input of which bioelectric signals from each microelectrode were received, which were preprocessed using a system for recording the focal activity of the olfactory analyzer. The specialists confirmed the presence or absence of a risk of lung cancer by a reference method, according to computed tomography of the chest in accordance with the Lung Imaging Reporting and Data System (LungRADS™). Results. During the study, experts determined the effectiveness indicators of the method of biohybrid lung cancer screening by exhaled air: sensitivity (64%), specificity (87%), prognosticality of negative and positive conclusions about the presence/absence of disease risk (82% and 72%, respectively). Conclusion. The safety, efficiency and throughput of the investigated method, together with the reproducibility of the analyzer's conclusions, meet the criteria of practicability to ensure the first (population-based) stage of lung cancer screening.

Thyroid status in patients with early stages of cancer of various localization

Purpose of the study. To determine the thyroid status of primary cancer patients in the early stages of uterine body cancer, kidney cancer, breast cancer, skin melanoma and lung cancer without a history of endocrine pathology.Patients and methods. The content levels of thyroid-stimulating hormone (TSH), thyroid hormones (THs) T4 and T3 of total and free forms were determined in the blood serum by RIA method in 132 patients with breast cancer, uterine body cancer, lung cancer, kidney cancer and skin melanoma (average age 55 years). The comparison group consisted of practically healthy donors.Results. Only in skin melanoma, serum TSH levels were reduced by 1.5 times (p &lt; 0.05). The T4 content was reduced by 1.4–1.7 times (p &lt; 0.05) in uterine body cancer and kidney cancer, increased in lung cancer patients and 16 % of breast cancer patients by 1.4–1.7 times though (p &lt; 0.05). A 1.3–1.5‑fold low (p &lt; 0.05) T3 level was found in breast cancer, kidney cancer, and skin melanoma, while an 1.6‑fold increase (p &lt; 0.05) was found in uterine body cancer. The revealed changes in THs by the type of clinical hyperthyroidism are an increase of 1.8 times (p &lt; 0.05) FT3 on the background of low TSH in the blood in patients with skin melanoma, and by the type of hyperthyroxinemia in patients with lung cancer and breast cancer, consisting in increased concentrations of T4 and FT3, and with free and total T3 levels in patients uterine body cancer, as well as FT4, without changes in TSH in the blood serum of patients, may be associated with the features of malignant pathology, since it is known that THs are proliferation stimulants and can build up in tumors.Conclusion. The development of a malignant tumor even in the early stages of the disease is perceived by the body as a threat for homeostasis and the response to the occurrence of neoplasm is the reaction of the hypothalamicpituitary-thyroid regulatory axis. As an outcome, patients develop euthyroid disorder syndrome.

Characterisations and Scan Findings of Non-Small Cell Lung Cancer Seen on Staging FDG PET-CT: Contemporary Review and Institutional Experience

Objective: Fluorodeoxyglucose (FDG) PET-CT scan is extensively being applied in oncology including lung cancer staging and treatment response assessment by depicting glucose consumption of malignant cells. Non- small cell lung cancer (NSCLC) cases such as adenocarcinoma and squamous cell carcinoma (SCC) are more prevalent. We aimed to determine the FDG uptake avidity based on semiquantitative maximum Standardise Uptake Value (SUVmax) observed on staging PET-CT of newly diagnosed NSCLC and associated contributing factors. Methods: Retrospective review of 125 cases of biopsy proven lung cancer referred for FDG PET-CT in our institution over the past 2 years. Staging PET-CT scans (n=54) were included for analysis. Clinical parameters and PET-CT findings (SUVmax of primary lesion, presence of nodal and metastatic disease) were investigated. SUVmax of primary lesion for SCC and adenocarcinoma was compared. Association between SUVmax of primary lesion and extrapulmonary FDG- avid lesions presence was also determined. Results: Males were predominant (60%). Average age was 62.5 years. Majority were adenocarcinoma (65%) followed by SCC (22%) and others (13%). Mean tumour size was 5.1 cm. Lung SCC demonstrated intensely increased FDG uptake that was significantly higher compared to adenocarcinoma (average SUVmax 24.4 vs SUVmax 15.6, p&lt;0.05). FDG-avid ipsilateral hilar nodal involvement seen in 63%, mediastinal nodes in 70% while distant metastatic disease in 33%. Patients having primary lesion with SUVmax 20.0 and above were significantly associated with larger tumour size and FDG-avid ipsilateral hilar nodal uptake (p&lt;0.05). Conclusion: Lung SCC was intensely FDG-avid and had higher SUVmax compared to adenocarcinoma. Primary lesions with SUVmax 20.0 and above were associated with larger tumour size and presence of hypermetabolic ipsilateral hilar nodal spread. Information obtained from this review will provide valuable insight into PET-CT scan characteristics of newly diagnosed NSCLC cases in our institution that may influence not only scan reporting formulation but also patient management.International Journal of Human and Health Sciences Supplementary Issue 01: 2024 Page: S46

Impact of OLD/Emphysema in LC Mortality Risk in Screening Programs: An Analysis of NLST and P-IELCAP

IntroductionThe impact of obstructive lung disease (OLD) and emphysema on lung cancer (LC) mortality in patients undergoing LC screening is controversial. MethodsPatients with spirometry and LC diagnosed within the first three rounds of screening were selected from the National Lung Screening Trial (NLST) and from the Pamplona International Early Lung Cancer Detection Program (P-IELCAP). Medical and demographic data, tumor characteristics, comorbidities and presence of emphysema were collected. The effect of OLD and emphysema on the risk of overall survival was assessed using unadjusted and adjusted Cox models, competing risk regression analysis, and propensity score matching. ResultsData from 353 patients with LC, including 291 with OLD and/or emphysema and 62 with neither, were analyzed. The median age was 67.3 years-old and 56.1% met OLD criteria, predominantly mild (1: 28.3%, 2: 65.2%). Emphysema was present in 69.4% of the patients. Patients with OLD and/or emphysema had worse survival on univariate analysis (HR: 1.40; 95% CI: 0.86–2.31; p=0.179). However, after adjusting for LC stage, age, and sex, the HR was 1.02 (95% CI: 0.61–1.70; p=0.952). Specific LC survival between both groups showed an adjusted HR of 0.90 (95% CI: 0.47–1.72; p=0.76). Propensity score matching found no statistically significant difference in overall survival (HR: 1.03; 95% CI: 0.59–1.9; p=0.929). ConclusionThe survival of LC patients diagnosed in the context of screening is not negatively impacted by the coexistence of mild OLD and/or emphysema.

Sentinel Lymph Node Mapping in Lung Cancer: A Pilot Study for the Detection of Micrometastases in Stage I Non-Small Cell Lung Cancer.

Lymphadenectomy represents a fundamental step in the staging and treatment of non-small cell lung cancer (NSCLC). To date, the extension of lymphadenectomy in early-stage NSCLC is a debated topic due to its possible complications. The detection of sentinel lymph nodes (SLNs) is a strategy that can improve the selection of patients in which a more extended lymphadenectomy is necessary. This pilot study aimed to refine lymph nodal staging in early-stage NSCLC patients who underwent robotic lung resection through the application of innovative intraoperative sentinel lymph node (SLN) identification and the pathological evaluation using one-step nucleic acid amplification (OSNA). Clinical N0 NSCLC patients planning to undergo robotic lung resection were selected. The day before surgery, all patients underwent radionuclide computed tomography (CT)-guided marking of the primary lung lesion and subsequently Single Photon Emission Computed Tomography (SPECT) to identify tracer migration and, consequently, the area with higher radioactivity. On the day of surgery, the lymph nodal radioactivity was detected intraoperatively using a gamma camera. SLN was defined as the lymph node with the highest numerical value of radioactivity. The OSNA amplification, detecting the mRNA of CK19, was used for the detection of nodal metastases in the lymph nodes, including SLN. From March to July 2021, a total of 8 patients (3 female; 5 male), with a mean age of 66 years (range 48-77), were enrolled in the study. No complications relating to the CT-guided marking or preoperative SPECT were found. An average of 5.3 lymph nodal stations were examined (range 2-8). N2 positivity was found in 3 out of 8 patients (37.5%). Consequently, pathological examination of lymph nodes with OSNA resulted in three upstages from the clinical IB stage to pathological IIIA stage. Moreover, in 1 patient (18%) with nodal upstaging, a positive node was intraoperatively identified as SLN. Comparing this protocol to the usual practice, no difference was found in terms of the operating time, conversion rate, and complication rate. Our preliminary experience suggests that sentinel lymph node detection, in association with the accurate pathological staging of cN0 patients achieved using OSNA, is safe and effective in the identification of metastasis, which is usually undetected by standard diagnostic methods.

The Impact of Model Assumptions on Personalized Lung Cancer Screening Recommendations.

Recommendations regarding personalized lung cancer screening are being informed by natural-history modeling. Therefore, understanding how differences in model assumptions affect model-based personalized screening recommendations is essential. Five Cancer Intervention and Surveillance Modeling Network (CISNET) models were evaluated. Lung cancer incidence, mortality, and stage distributions were compared across 4 theoretical scenarios to assess model assumptions regarding 1) sojourn times, 2) stage-specific sensitivities, and 3) screening-induced lung cancer mortality reductions. Analyses were stratified by sex and smoking behavior. Most cancers had sojourn times <5 y (model range [MR]; lowest to highest value across models: 83.5%-98.7% of cancers). However, cancer aggressiveness still varied across models, as demonstrated by differences in proportions of cancers with sojourn times <2 y (MR: 42.5%-64.6%) and 2 to 4 y (MR: 28.8%-43.6%). Stage-specific sensitivity varied, particularly for stage I (MR: 31.3%-91.5%). Screening reduced stage IV incidence in most models for 1 y postscreening; increased sensitivity prolonged this period to 2 to 5 y. Screening-induced lung cancer mortality reductions among lung cancers detected at screening ranged widely (MR: 14.6%-48.9%), demonstrating variations in modeled treatment effectiveness of screen-detected cases. All models assumed longer sojourn times and greater screening-induced lung cancer mortality reductions for women. Models assuming differences in cancer epidemiology by smoking behaviors assumed shorter sojourn times and lower screening-induced lung cancer mortality reductions for heavy smokers. Model-based personalized screening recommendations are primarily driven by assumptions regarding sojourn times (favoring longer intervals for groups more likely to develop less aggressive cancers), sensitivity (higher sensitivities favoring longer intervals), and screening-induced mortality reductions (greater reductions favoring shorter intervals). Models suggest longer screening intervals may be feasible and benefits may be greater for women and light smokers. Natural-history models are increasingly used to inform lung cancer screening, but causes for variations between models are difficult to assess.This is the first evaluation of these causes and their impact on personalized screening recommendations through easily interpretable metrics.Models vary regarding sojourn times, stage-specific sensitivities, and screening-induced lung cancer mortality reductions.Model outcomes were similar in predicting greater screening benefits for women and potentially light smokers. Longer screening intervals may be feasible for women and light smokers.

Study on the difference and regularity of tongue images in 309 patients with different pathological stages of non-small cell lung cancer.

Tongue diagnosis is a crucial traditional Chinese medicine (TCM) inspection method for TCM syndrome differentiation and treatment. The primary research focus was on tongue image characteristic parameters of patients with non-small cell lung cancer (NSCLC). Analysis of the tongue image parameters of various pathological stages of NSCLC provides technical support for establishing an integrated Chinese and Western auxiliary diagnosis and efficacy evaluation medicine system for lung cancer that integrates tongue image features. Tongue image characteristics of 309 patients with NSCLC and 206 controls were collected and analyzed clinically. The T-test or rank sum test and logistic regression analysis were applied to analyze the characteristics of tongue image indicators of different pathological stages of NSCLC. There were differences in tongue image characteristics in the NSCLC group compared to the control group. The tongue quality and brightness of the tongue coating in the NSCLC group increased, the red component was reduced, the tongue coating thickened, and the yellow component increased compared to the healthy control group. A comparison of tongue image indexes of NSCLC in different pathological stages showed that stage IV had lower TB-b and higher TB-a than stage I. In addition, stage IV had lower TB-b than stage II + III, showing an increase in the blue and red components of the tongue in stage IV and the appearance of cyanotic tongue features. The tongue image characteristics of NSCLC patients differed from those of the control group. Tongue imaging indicators can reflect the characteristics of tongue images of patients with NSCLC. The tongue image characteristics of patients with stage IV lung cancer are bluish and purple compared with those with stage I, II, and III. It is suggested that the tongue's image characteristics can be used as a reference for the pathological classification of NSCLC and judgment of the disease process.